Christopher J. Waddick
CFO, Corporate Secretary & DirectorMr. Christopher J. Waddick, also known as Chris, CMA., MBA, CPA, CA, has been the Chief Financial Officer at Cardiol Therapeutics Inc. since August 16, 2018 and serves as its Corporate Secretary and also serves as its Director since May 19, 2022. Mr. Waddick served as Chief Executive Officer and President of Vasogen Inc. since June 20, 2007. Mr. Waddick served as Chief Operating Officer of Vasogen since December 15, 2005, and also served as its Executive Vice President, Treasurer and Corporate Secretary. He served as Chief Financial Officer from April 11, 2007 to July 10, 2007 and also from 1997 to 2005. He has experience in financial and executive roles in the biotechnology and energy industries, with substantial knowledge of public company management and corporate governance, and in designing, building, and managing financial processes, procedures, and infrastructure. Mr. Waddick most recently served as Executive Vice President and Chief Financial Officer for a private Ontario energy company where he was retained by the shareholders to refinance the company and establish a new strategic direction, as well as the appropriate financial infrastructure. During his tenure, he implemented two corporate restructurings, drove substantial earnings growth, and significantly reduced both cost of capital and debt levels. Mr. Waddick spent many years at Vasogen Inc., a biotechnology company focused on the research and commercial development of novel therapeutics for the treatment of heart failure and other inflammatory conditions. He joined Vasogen Inc. in 1997 and has played a key role in establishing its growth and strategic direction. Prior to joining Vasogen Inc., he held a series of financial and regulatory roles in the energy and automotive sectors. While serving as Chief Financial Officer and Chief Operating Officer, the company grew from start-up to an organization employing over 250 employees that established the necessary systems and infrastructure to advance an anti-inflammatory therapy through to the completion of an international multi-center pivotal trial involving 2,500 patients. Prior to Vasogen, he held progressively senior financial positions at Magna International Inc. and Union Gas Limited. Mr. Waddick is a CPA and earned a business degree from Wilfrid Laurier University and holds an MBA from York University in Toronto.
Positions
- Company NameCardiol Therapeutics Inc.Stock CodeCRDLPositionCFO, Corporate Secretary & DirectorColleagues
